Millions can’t afford prescriptions
More than 13 percent of American adults — or about 34 million people — report knowing of at least one friend or family member in the past five years who died after not receiving needed medical treatment because they were unable to pay for it, based on a new study by Gallup and West Health.
Nonwhites, those in lower-income households, those younger than 45, and political independents and Democrats are all more likely to know someone who has died under these circumstances.
Dovetailing with these results is a rising percentage of adults who report not having had enough money in the past 12 months to “pay for needed medicine or drugs that a doctor prescribed” to them.
This percentage has increased significantly, from 18.9 percent in January 2019 to 22.9 percent in September.
In all, the 22.9 percent represents about 58 million adults who experienced “medication insecurity,” defined as the inability to pay for prescribed medication at least one time in the past 12 months.
The increase reflects a marked rise among women of over five percentage points to 27.5 percent, widening the gender gap to over nine points when compared with the 18.1 percent rate for men. And while data among both political independents and Republicans are statistically unchanged since September, medication insecurity among Democrats has risen over six points to 27.7 percent.
Against a backdrop of millions of Americans who know people who have died after not being able to afford needed treatment, and millions more recently experiencing medication insecurity personally, most respondents agree that U.S. consumers are paying too much for prescription drugs.
Close to nine in 10 U.S. adults report that the costs of prescription drugs are “usually much higher” (69 percent) or “tend to be somewhat higher” (20 percent) than what consumers should be paying for them, compared with only 1 percent who believe them to be much or somewhat lower. These perceptions are shared by political and demographic subgroups, with only modest differences between groups in the percentage viewing drug prices as too high.
While perspectives on the price of medicine relative to what consumers should be spending are largely uniform, perspectives regarding President Donald Trump’s success at curtailing rising drug prices are more divided along party lines.
When asked, “How much progress has the Trump administration made to limit the rising cost of prescription drugs in the U.S.?” two-thirds of respondents — split evenly — report “not very much” progress or “none at all.”
But only 31 percent of Republicans express this sentiment, compared with 66 percent of independents and 96 percent of Democrats. Nearly nine out of 10 adults who disapprove of the job Trump is doing also report little to no progress.
The substantial number of Americans who know someone who has died after not receiving treatment because of their inability to pay for it, coupled with the rise in the percentage who have not had enough money to pay for their prescriptions, underscores the urgency of the U.S. healthcare cost crisis. These realities starkly highlight the significant practical implications of drug prices on U.S. residents, as well as the effects of health care policy action — or inaction.
Drug prices directly affect consumers, and with the U.S. one year away from the 2020 election, presidential candidates will increasingly be asked to explain and defend their policy positions regarding rising drug costs.
Only 7 percent of U.S. adults report that the Trump administration has accomplished “a great deal” on the issue, and voters are clearly expecting more from their elected officials than what has been accomplished in the past three years.
In Congress, meanwhile, the U.S. House of Representatives is expected to vote soon on House Democrats’ plan to curb soaring prescription drug prices by allowing the federal government to negotiate prices of certain drugs, including insulin products and single-source brand-name drugs with no generic competition.
The U.S. Senate is considering a separate, bipartisan proposal that would cap seniors’ out-of-pocket costs and require drug manufacturers to reimburse Medicare if prices rise more than the inflation rate.